Cellular immunity to Bacteroides fragilis capsular polysaccharide by unknown
CELLULAR  IMMUNITY  TO  BACTEROIDES  FRAGILIS 
CAPSULAR  POLYSACCHARIDE* 
BY MICHAEL  E.  SHAPIRO,:~ ANDREW  B.  ONDERDONK, DENNIS  L.  KASPER, 
AND ROBERT  W.  FINBERG§ 
From the Department of Surgery and Division of lnfectious Diseases, Beth Israel Hospita#  the Channing 
Laboratory and Division of lnfectious Diseases, Brigham and Women's Hospital; the Departments of 
Pathology, Medicine, and Surgery, Harvard Medical School, Boston, Massachusetts 02115; and the 
Infectious Disease Research Laboratory, Tufts  University Schools of Veterinary Medicine and Medicine, 
Boston, Massachusetts 02l I t 
Bacteroidesfragilis,  an anaerobic bacterium that accounts for only a small fraction of 
the  colonic  microflora,  is  the  most  frequently  isolated  anaerobic  species  in  many 
infectious processes (1), including intraabdominal  sepsis (2). Strains of B. fragilis have 
a polysaccharide antigen on their surface that is not present on other Bacteroides species 
(3, 4).  B. fragilis is unique among anaerobes in its ability to induce abscesses by itself, 
and  in  a  rat  model  of intraabdominal  sepsis,  this  ability  has  been  shown  to  be 
dependent  upon the presence of the polysaccharide capsule  (5, 6). It has been shown 
that  rats  immunized  with  this  capsular  polysaccharide  (CP) 1 are  protected  from 
intraabdominal abscess formation and bacteremia caused by this organism (7).  In the 
rat,  this  protection  can  be  passively  transferred  by nylon  wool nonadherent  spleen 
cells (8). 
To  better  define  the  immune  response  to  B. fragilis,  we  have  developed  a  new 
experimental model for intraabdominal sepsis using the mouse. This model has several 
features  that  make  it  preferable  to other previously described  model  systems  (5,  9). 
The rat model of intraabdominal sepsis (5)  has the disadvantage of requiring surgical 
implantation  of the inoculum, and both a  gelatin capsule and BaSO4 are required in 
order to obtain uniform abscess development. The murine model described by Joiner 
et al.  (9)  involved subcutaneous implantation  of the inoculum, resulting in subcuta- 
neous abscesses  at  the  site  of inoculation.  The  model  described  below  more closely 
parallels  disease in humans because no vehicle is required,  and the result  is intraper- 
itoneal abscess formation. The use of sterile cecal contents provides a  medium similar 
to that encountered in naturally occurring intraabdominal  sepsis. 
In the studies  detailed  below, we have shown that  mice immunized  with  CP  are 
immune to the development  of abscesses,  and that  this  immunity is a  function of T 
cells. The immune response is mediated by an antigen-specific, but non-H-2-restricted 
Ly-l-2  + cell.  The application  of this  model to the study of immune responses to T- 
independent polysaccharides is discussed. 
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Materials and Methods 
Mice.  C57BL/10J (H-2~, B10.D2  (H-2d), and B10.BR (H-2  k) mice were obtained from The 
Jackson Laboratory, Bar Harbor, ME, and maintained on Purina mouse chow and water ad 
libitum. Animals were  housed  in cages  containing --~10 animals each.  Incoming mice were 
screened by viral serology  for the presence of active murine viral infection, and were used at 
8-16 wk of age. 
Bacterial  Strains.  Cultures of B. fragilis  (American Type Culture Collection ATCC 23745) 
were obtained from  the stock culture collection of the Channing Laboratory, Boston, MA. 
Cultures of Fusobacterium varium  (TVDL 3) and enterococcus (TVDL 41) were obtained from 
the stock culture collection of the Tufts University Veterinary Diagnostic Laboratory, Boston, 
MA.  All cultures were  grown  in  prereduced  peptone  yeast  glucose  medium  (PYG;  Scott 
Laboratories, Fiskeville, RI) within an anaerobic isolator (Labline Instruments, Melrose Park, 
IL) for 24-48 h.  After incubation, cultures were divided into 5-ml aliquots, placed into gas- 
tight vials, and frozen at -70°C until used. 
Immunization.  The preparation of the B. fragilis  capsular polysaccharide antigen used for 
those studies has  been described previously (3). The antigen is free  of contamination with 
protein or lipopolysaceharide. Amino acid  analysis of the  polysaccharide shows  only trace 
quantities of all amino acids, except for alanine, which accounts for 3.8% of the antigen (D. L. 
Kasper, A. Weintraub, J. Lonngren, and A. A. Lindberg, manuscript in preparation). 
C57BL/10J mice were immunized subcutaneously with  10 #g of CP in 0.1  ml PBS three 
times a week for 3 wk. The animals received a booster injection on week 5, and were available 
for challenge or adoptive transfer experiments on week 6. 
Cell Transfers.  Spleens were removed from immunized or naive mice and gently teased in 
L-15 medium (M. A. Bioproducts, Walkersville, MD) supplemented with 5% fetal calf serum. 
Spleen cells were counted using a Coulter FN counter (Coulter Electronics Inc., Hialeah, FL) 
and examined for  viability by trypan blue exclusion. After washing,  the  cell density was 
adjusted to  12.5 ×  10  e cells/ml with medium and 2.5 ×  106 spleen cells were transferred in a 
0.2-ml vol by intracardiac injection. 
Monoclonal Antibody.  In some experiments, spleen cells were treated with monoclonal anti- 
Thy-l.2, anti-Ly-l.2, or anti-Ly-2.2 antibody (New England Nuclear, Boston, MA). The anti° 
Thy-1.2 was used at a  1:200 dilution, and the anti-Ly antibodies were used at 1:100. Cells were 
incubated in 0.5  ml of reagent per 50  X  106 cells for 45 min at 4°C. After incubation with 
antibody, cells were washed once and then incubated with rabbit Low-M-Tox complement 
(Cederlane Laboratory, Hornby, Ontario) diluted 1:6 with medium for 45 min at 37°C. After 
complement treatment, cells were washed once and the antibody-complement treatment was 
repeated a second time. The cells were then washed three times before transfer. Efficiency of 
antibody-complement treatment was confirmed by allogeneic proliferation and cytotoxic T 
lymphocyte assays. Immune cells were obtained from mice immunized for 8-12 wk. 
Immune Serum Transfer.  Immune mice were bled by retro-orbital puncture, and the sera were 
pooled. 0.2 ml of serum was transferred by intracardiac injection. 
Serological Methods.  Serum was obtained at the time of necropsy after bacterial challenge. 
Antibody to  the  B. fragilis  CP  was  quantitated by  the  radioactive antigen binding assay 
described previously (10). 
Preparation of Bacterial  Challenge.  Quantitative determinations of viable cell  density were 
made by means of direct  plate counts of each  strain after freezing of the original culture 
preparations. Samples of each bacterial strain were thawed within an anaerobic chamber and 
TABLE  I 
Protective Effect of Immunization  with CP on B. fragilis Abscess Formation 
Immunization status  Inoculum  Abscess incidence* 
Nonimmunized control  106 CFU B. fragilis~  9/9 
Immunized B. fragilis CP  106 CFU B. fragilis  2/10 (P < 0.001) 
* Number with abscesses/number challenged. 
~: 50:50 with sterile cecal contents in 0.1-ml vol intraperitoneally. 1190  CELLULAR  IMMUNITY  TO  B.  FRAGILIS  POLYSACCHARIDE 
FIG.  1.  Intraperitoneal abscesses in BALB/c mice. Mice were challenged with 10  s CFU B. fragilis 
and necropsied  6 d  later.  Arrows  identify abscesses adherent to the parietal peritoneum (A) and 
between intestinal loops (B). 
serial  10-fold dilutions were made using sterile dilution salts (11).  Duplicate 0.1-ml portions of 
each  dilution  were  plated  onto  Brucella-base  blood  agar  and  allowed  to  dry.  Plates  were 
incubated for 48 h at 37°C within an anaerobic chamber and colonies were enumerated. Before 
implantation, bacterial cultures were diluted to the appropriate concentration with sterile PYG 
broth (12). 
Bacterial Challenge.  106 colony-forming units (CFU) of viable B. fragilis (ATCC 23745)  were 
mixed 50:50 vol/vol with sterile cecal contents from meat-fed rats, and injected intraperitoneally 
into mice in a volume of 0.1 cc. In the specificity control, 5 ×  10  v CFU F. varium (TVDL3) and 
5 ×  10 z CFU enterococcus (TVDL41)  were mixed with sterile cecal contents and injected in a 
similar manner. The larger inoculum of these bacteria was required to produce abscesses. Mice 
were challenged 24 h after cell transfers. 
Assessment of Results.  All animals were necropsied in a  blinded fashion 6  d  after bacterial SHAPIRO  ET  AL.  1191 
FIG. 1B 
challenge. Animals were considered to have an intraabdominal abscess if one or more loculated 
collections were identified containing a  grossly purulent  exudate that showed polymorphonu- 
clear leukocytes and bacteria on Gram stain. Each abscess was cultured to confirm the presence 
of  the  appropriate  bacterial  species  and  to  ensure  that  contamination  had  not  occurred. 
Statistical comparisons of the various groups were made by X  3  analysis (13).  Data are expressed 
as:  percent  protection  -~  100  ×  (1  -  number with abscesses/number  in group). Thus,  percent 
protection refers to the fraction of mice that had no abscesses. All experiments were performed 
at least twice. 
Results 
Effect  of Immunization  with  CP on  Abscess  Formation  in  Mice.  C57BL/10  mice  were 
immunized  with  10 ~g CP without  adjuvants three times a  week for 3 wk, and weekly 
boosters  were  given  beginning  at  week  5.  Immune  mice  and  normal  controls  were 1192  CELLULAR  IMMUNITY TO B.  FRAGILIS POLYSACCHARIDE 
challenged with  106 CFU  live B. fragilis and sterile cecal contents, and necropsied 7 d 
later  (Table I).  Fig.  1 demonstrates the typical appearance of the B. fragilis-induced 
abscesses  in  these  mice.  Abscesses  were  found  in  only  2  of  10  immunized  mice  as 
compared with 9  of 9  normal controls (P <  0,001). This indicates that  immunization 
with polysaccharide confers protection against abscess formation. 
Role of Cellular Immunity in Protection against Abscess.  To determine what was respon- 
sible for  protection  against  abscess  formation,  serum or cells were  transferred  from 
immune  animals into naive recipients. Mice received either 2.5  X  106 spleen cells or 
0.2  ml of serum  from  CP-immunized  mice by intracardiac  injection. Immune  cells 
were  protective  in  10 of  10  mice  (Fig.  2),  whereas  immune  serum was  not  (0 of  10 
mice; P  <  0.001).  As expected,  anti-CP antibody titers were higher in the mice that 
received serum (data not shown). 
Antigen Specificity  of Immune Cells.  Mice received 2.5 ×  106 spleen cells from immune 
donors or normal controls, and were challenged with either B. fragilis or a  mixture of 
F.  varium/enterococcus  (both  bacteria  are  required  for  abscess  formation).  Immune 
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Fie.  2.  Passive transfer of immunity  to B. fragilis abscesses with serum or spleen cells from immune 
donors. 2.5 X 10  ° spleen cells or 0.2 ml of serum from immunized mice was transferred  to C57BL/ 
10 mice that were challenged 24 h later with l0  s CFU B. fragilis. Necropsy was performed  on day 
7. The fractions indicate (number of mice without abscess)/(number of mice in group). 
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FIG. 3.  Specificity  of the passive protection against abscesses afforded  by spleen  cells from  B. 
fragilis CP-immunized mice. Spleen cells were transferred  as described  (from either immunized or 
nonimmunized donors). Mice were challenged 24 h later with either 106 CFU B. fragilis or 5 ×  107 
CFU F. varium and 5 ×  107 CFU enterococcus. The difference between the two fuso/entero groups 
is not significant (P > 0.1). SHAPIRO ET  AL. 
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FIC. 4.  Anti-Thy-  1.2 plus complement treatment of immune spleen cells. Before transfer, immune 
cells were incubated with monoclonal anti-Thy-1.2 antibody and complement or complement alone 
as described. 
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FIo. 5.  Lyt phenotype  of immune  spleen cells. Before transfer, immune  cells were treated with 
monoclonal Ly-l.2 plus complement, Ly-2.2 plus complement, or complement alone as described. 
2.5 ×  106 cells were then transferred into nonimmune recipient mice. Immune cells were from mice 
immunized for 8-12 wk. 
cells protected against B. fragilis  abscesses (P <  0.01)  (Fig. 3), but not those caused by 
a  combination of F. varium/enterococcus  (P >  0.1). 
Surface Antigen Phenotyping of Immune Cells.  Immune spleen cells were treated with 
anti-Thy-l.2 plus complement  before transfer to deplete T  cells. Anti-Thy-l.2 com- 
pletely abolished the immune response  (P <  0.001), whereas complement alone had 
no  effect  on  the  cells treated  (Fig.  4),  identifying the  immune  cell as a  T  cell. To 
further  identify the cell, its Ly phenotype was  determined  (Fig. 5).  Pretreatment  of 
immune  spleen cells with  anti-Ly-l.2 before transfer had  no effect on  the ability of 
the  cells to  prevent  abscesses.  Anti-Ly-2.2  treatment  abrogated  the  response  (P  < 
0.01).  Thus,  the  immune  cell  is  Ly-l-2  +.  The  efficacy  of  the  anti-Ly-l.2  plus 
complement treatment was confirmed by the elimination of an allogeneic proliferative 
response.  Treatment  with  anti-Ly-2.2  did  not  affect  the  allogeneic  proliferative 
response, but  did prevent an  allogeneic cytotoxic response. At the time of necropsy, 1194  CELLULAR  IMMUNITY  TO  B.  FRAGILIS  POLYSACCttARIDE 
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Fic.  6.  Transfer of immune spleen cells into H-2 congenic mice. 2.5 X  l0  ~ immune or nonimmune 
C57BL/10 spleen cells were transferred  into either syngeneic or BI0.D2 congenic mice. Challenge 
with B. fragih's was as described. 
animals  from  all  groups  had  equivalent  amounts  of anti-CP  antibody  (data  not 
shown). 
H-2 Restriction  of Immune  Cells.  2.5  ×  106 immune cells from C57BL/10J  (H-2  b) 
mice  were  transferred  into  syngeneic or  allogeneic  (B10.D2,  H-2  d)  mice  (Fig.  6). 
Immune cells were significantly effective (P <  0.05)  in preventing abscess formation 
in allogeneic as well as in syngeneic mice. Similar results were obtained with transfers 
into B 10.BR (H-2  k) mice (data not shown). Those results indicate that the protective 
action of the immune T  cells is not H-2 restricted. 
Discussion 
The above experiments demonstrate the importance of cellular immunity (in vivo) 
to  a  polysaccharide antigen  using  a  new  murine  model  of intraabdominal  sepsis. 
Previous  studies  have  reported  that  rats  immunized  with  the  B.  fragilis  CP  are 
protected against abscess development and bacteremia in an experimental model of 
intraabdominal sepsis (7).  In further investigating this phenomenon, it was reported 
that protection against  abscess formation could be passively transferred by immune 
spleen cells (8). Immune cells resided in the nylon wool nonadherent fraction of spleen 
cells, which suggested that this was a T  cell-dependent phenomenon (8). 
We  have  been  able  to  show  that  mice  immunized  with  the  purified  capsular 
polysaccharide from B. fragilis develop specific immunity as measured by protection 
against  abscess  formation  (Table I).  To examine this phenomenon in  more detail, 
adoptive transfer experiments were used. The protection against abscesses is a cellular 
rather than humoral function. All animals tested develop specific anti-CP antibody 
during the period of bacterial challenge. Because the animals in the serum transfer 
group had higher antibody levels without protection against  abscesses, we conclude 
that merely transferring helper T  cells (with resultant higher antibody levels) cannot 
account for the protection observed. Moreover, the cell(s)  involved in  this immune 
response  were  identified  as  T  cells  belonging  to  the  Ly-l-2  +  subset.  Thus,  the 
responsible cell is unlikely to be a T  helper cell, which would be expected to have an 
Ly- I +2- phenotype. SHAPIRO ET AL.  1195 
Bacterial polysaccharides have classically been thought of as T-independent  (TI) 
antigens.  These antigens  have been considered capable of generating antibody re- 
sponses (primarily IgM in mice) in the absence of T  cells and to be poor inducers of 
immunologic memory (14). In this sense the B. fragilis CP is a TI antigen and antibody 
responses  can  be  obtained  using  nude  rats  (8)  and  nude  mice  (data  not  shown). 
Studies of the  type III  pneumococcal polysaccharide by Baker et  al.  (15,  16)  and 
Braley-Mullen  (17,  18)  have demonstrated that  these putative TI responses can be 
amplified or suppressed by appropriately primed T  cells.  Recent work by Mond et al. 
(14)  and  Letvin et al.  (19)  has demonstrated a  T  cell requirement  for the plaque- 
forming cell  response  to  trinitrophenyl-Ficoll,  another  TI  antigen.  These  authors 
suggest that helper T  cells may be relevant to certain TI antigen responses in much 
the same way that T-dependent responses are controlled. 
The T  cell modulation of TI antigen  responses reported by others  (14-19)  have 
dealt with modification of B cell responses as measured by plaque-forming cell assays. 
Our model is entirely different. We have shown that T  cells are capable of preventing 
abdominal  abscesses.  It  is  not  known  how  the  protective effect against  B. fragilis 
abscesses is  mediated,  but  antibody production does not  appear to play a  decisive 
role.  Cellular  interactions  relevant  to  abscess  induction  have not  been  adequately 
defined. At the cellular level, histological examination has revealed that abscesses are 
collections of polymorphonuclear leukocytes, macrophages, and bacteria with varying 
amounts of necrotic debris. Early in abscess formation (19 h), the polymorphonuclear 
leukocyte is  the  predominant  cell type, whereas  later on  (>93  h)  the  macrophage 
dominates (20).  Lymphocytes do not appear to account for >2-3% of the cells in the 
abscess  at  any  time  (20).  Whether  lymphocytes play  a  role  in  the  chemotaxis  of 
neutrophils and macrophages to form abscesses has not been demonstrated. 
What type of T  cell is responsible for the immune response reported here? It is~not 
possible at this time to assign the cell(s) to any particular previously defined subset. 
Our data indicate that antigen-specific T cells are involved in the control of abscesses. 
The antigen-specific cell, however, is not H-2 restricted and is Ly-l-2  ÷. Clearly, the 
cell is not a  conventional cytotoxic or helper T  cell. Both helper and cytotoxic cells 
act in an H-2-restricted manner. Cytotoxic cells are generally active against intracel- 
lular organisms, but not against soluble antigens or free bacteria. One might speculate 
that the immune T  cell population is composed of suppressor cells.  If this is so, what 
immune function is being suppressed? One possibility is that there is T  cell control of 
the macrophage/neutrophil response that ultimately results in abscess formation. In 
this case, the transferred cells might  be acting on abscess inducer T  cells.  Whether 
these putative inducer cells are stimulated  by polysaccharide or protein antigens is 
another question that must be addressed. Recently Geha et al. (21)  have described a 
suppressor  cell  defect  in  a  human  syndrome resulting  in  recurrent  staphylococcal 
abscesses. 
Although abscess formation is usually regarded as a host defense mechanism, it can 
also be regarded as a granulocyte failure that favors the persistence of bacteria. Thus, 
another possible interpretation of these data is that T  cells prevent the bacteria from 
becoming established at all. This would explain the ability of the T  cells to prevent 
abscess formation by implying that an effector T  cell is active against bacteria. Such 
a T  cell could function directly by binding or inactivating bacteria, or (more likely) 
by  releasing  a  lymphokine that  activates  or  attracts  macrophages.  It  will  require 1196  CELLULAR IMMUNITY TO  B.  FRAGILIS  POLYSACCHARIDE 
further study to define the interactions occurring in  the recipient  animal to answer 
these questions. 
A  recent report suggests that T  lymphocytes play a  role in the defense against B. 
fragilis  in  humans.  In  a  series  of  patients  who  underwent  appendectomy  while 
immunosuppressed for renal transplantation,  four patients developed B. fragilis  bac- 
teremia,  and  two  had  intraabdominal  abscesses  from  which  only  B.  fragilis  was 
cultured (22).  All patients who received anti-thymocyte globulin and had appendec- 
tomies developed B. fragilis  bacteremia. Thus, T  cells  may be involved in immunity 
to B. fragilis  in humans. 
Summary 
The polysaccharide capsule of Bacteroidesfragilis  has been shown to be important in 
the virulence of the organism. The capsular polysaccharide (CP) of B. fragilis has been 
extensively purified. Using a  murine model of intraabdominal abscess formation, we 
have been able to demonstrate cellular immunity to the capsular polysaccharide of B. 
fragilis.  Immunization of C57BL/10J mice with  the CP over 5 wk prevents abscess 
formation  when  the  mice  are  challenged  with  B.  fragilis  intraperitoneally.  This 
immunity can be transferred  to naive mice with spleen cells  from immune animals. 
The immune cells bear Thy-l.2 and Ly-2.2 antigens. The immune response has been 
shown to be antigen specific, but not H-2 restricted. The possibility that these immune 
cells  are suppressor T  cells  is discussed. The experimental system presented provides 
a  model  for  the  examination  of the  cellular  interactions  responsible  for  abscess 
formation and the cellular response to bacterial pathogens. 
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